Aurora Cannabis Taps Biopharma Veteran to Drive Global Medical Cannabis Expansion
Event summary
- Aurora Cannabis appoints Faris El Refaie as EVP, Global Commercial effective September 28, 2026.
- El Refaie brings 25 years of biopharmaceutical experience from JAMP Pharma Group, GSK, and AstraZeneca.
- New role focuses on accelerating commercial capabilities in Canada, Europe, Australia, New Zealand, and other international markets.
- Appointment underscores Aurora's push to strengthen its global medical cannabis platform.
The big picture
Aurora's appointment of a seasoned biopharmaceutical executive signals a strategic pivot towards leveraging commercial expertise from traditional pharma to drive growth in the medical cannabis sector. This move comes as the company seeks to solidify its position in an increasingly competitive and regulated global market. The focus on aligning its global portfolio and accelerating commercial capabilities highlights Aurora's ambition to expand its footprint beyond Canada into Europe, Australia, and New Zealand.
What we're watching
- Commercial Execution
- How Faris El Refaie's biopharmaceutical expertise will translate to Aurora's medical cannabis business.
- Market Penetration
- Whether Aurora can sustain its leadership in key international medical cannabis markets.
- Regulatory Dynamics
- The pace at which regulatory environments in target markets will evolve to support medical cannabis expansion.